Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.
The once-monthly injection, which will be sold under the brand name Rivfloza, is approved for use in children who are 9 years of age and older and adults with a type of primary hyperoxaluria and relatively preserved kidney function.
A general view of the headquarters of Danish pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (REUTERS/Tom Little/File photo / Reuters Photos)
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones.
The Danish drugmaker gained access to the therapy through its $3.3 billion buyout of Dicerna Pharmaceuticals.